AstraZeneca PLCAZNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank64
3Y CAGR-55.4%
5Y CAGR-37.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-55.4%/yr
vs +104.4%/yr prior
5Y CAGR
-37.0%/yr
Recent deceleration
Acceleration
-159.8pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 7.87% |
| Q3 2025 | 4.51% |
| Q2 2025 | 8.21% |
| Q1 2025 | -16.68% |
| Q4 2024 | 5.01% |
| Q3 2024 | 4.49% |
| Q2 2024 | 9.31% |
| Q1 2024 | -16.06% |
| Q4 2023 | 11.91% |
| Q3 2023 | -3.67% |
| Q2 2023 | 22.04% |
| Q1 2023 | -49.57% |
| Q4 2022 | 88.83% |
| Q3 2022 | -8.46% |
| Q2 2022 | -3.12% |
| Q1 2022 | -34.04% |
| Q4 2021 | 78.79% |
| Q3 2021 | 31.52% |
| Q2 2021 | 5.71% |
| Q1 2021 | -40.42% |
| Q4 2020 | 79.64% |
| Q3 2020 | 3.29% |
| Q2 2020 | -2.39% |
| Q1 2020 | -14.06% |
| Q4 2019 | -0.67% |
| Q3 2019 | 8.70% |
| Q2 2019 | 16.67% |
| Q1 2019 | -3.75% |
| Q4 2018 | 9.03% |
| Q3 2018 | -6.26% |
| Q2 2018 | 3.82% |
| Q1 2018 | -13.17% |
| Q4 2017 | 13.60% |
| Q3 2017 | 5.88% |
| Q2 2017 | 2.23% |
| Q1 2017 | 61.81% |
| Q4 2016 | -40.74% |
| Q3 2016 | -21.13% |
| Q2 2016 | 18.69% |
| Q1 2016 | -4.30% |